Hints and tips:
...“I feel very strongly that we should get as many shots in arms as possible, right away,” Mr Gottlieb told USA Today last week. “The reality is that one dose is partially protective....
...In particular, WBA pointed to a 2.3 per cent year-on-year rise in sales at its main Retail Pharmacy USA division, with a rise in pharmacy sales offsetting declining retail sales....
...In September last year, Novartis said it would sell parts of the Sandoz US business to Aurobindo Pharma USA to focus on “higher growth areas”....
...On Thursday, Novartis said it would sell portions of the Sandoz US portfolio to Aurobindo Pharma USA in order to focus on “higher growth areas”....
...“Anyone with the appetite and dollars to buy can, whether it’s a Patrick Soon-Shiong [the pharmaceuticals billionaire who owns the LA Times] or an Alden.”...
...The companies now under investigation are: Heritage Pharmaceuticals, Inc.; Aurobindo Pharma USA, Inc.; Citron Pharma, LLC; Mayne Pharma (USA), Inc.; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals USA;...
...Mass drug administration, supported by donations from a dozen pharmaceutical groups, plays an important part in this success. Fresh innovation is needed to produce better medicines and diagnostics....
...Taking the podium alongside Mr Gou at the White House, President Trump said it was a “great day” for “everyone who believes in Made in the USA” and claimed personal credit for Mr Gou’s investment....
...Following the pharma theme, Glenmark Pharmaceuticals needs the US for 34 per cent of its sales and has a 21 per cent correlation....
...Mr Schneider’s background in healthcare suggests he will seek growth opportunities for Nestlé’s fledgling “health science” division, which is pushing the group closer towards a pharmaceuticals business....
...Mr Soon-Shiong, 63, is a surgeon and scientist, known for pioneering diabetes and cancer therapies and has founded a number of pharmaceuticals companies, including American Pharmaceutical Partners and Abraxis...
...A California billionaire who has long coveted the Los Angeles Times has acquired a 13 per cent stake in Tribune Publishing, its parent company, which is being stalked by rival Gannett, the owner of USA Today...
...The results added pressure on Mr Ferro to negotiate with Gannett, owner of USA Today, which has offered to buy the smaller newspaper publisher for $15 a share — double the value of its stock price two months...
...Philip Gioia, previously president of North America at Glenmark Pharmaceuticals, a Mumbai-based drug developer, will explore opportunities in the biopharmaceuticals sector, while Richard Hassett, formerly...
...Mr Gisserot was previously co-head of GSK’s pharmaceutical business in Europe.”...
...The US subsidiary of Ranbaxy Laboratories, India’s biggest pharmaceuticals group, has pleaded guilty to felony charges related to drug safety and will pay $500m in what the US Department of Justice called...
Generic competition will kill the buzz
...MetroPCS was down 9.8 per cent to $12.24 on reports that its board had approved a merger deal with T-Mobile USA, a Deutsche Telekom subsidiary....
...Healthcare stocks led the gains on the S&P 500 index, with the sector gaining 1.4 per cent after positive news from pharmaceutical companies....
...Last year, US regulators opposed the $39bn purchase of T-Mobile USA, the mobile phone operator, by AT&T, the US telecommunications group, and Nasdaq OMX’s bid for NYSE Euronext – eventually spelling the...
...Big pharmaceutical companies had been using Facebook pages to promote their drugs....
...The takeover is the second-largest deal in the US this year after AT&T’s planned acquisition of T-Mobile USA....
...In the 1970s, a third group, Synthes USA, became involved. Over the past decade, the groups involved consolidated, with Hansjörg Wyss, the Swiss entrepreneur behind Synthes USA, becoming dominant....
...Pharmaceutical companies make a strategic choice between spending on research and development and spending on acquisitions....
...Valeant , an acquisitive speciality pharmaceutical company, said it was making a $5.7bn hostile offer for Cephalon, another drugmaker....
International Edition